8-K: Schrdinger Reports Strong 2025 Results, Targets 2028 Profitability

Schrdinger, Inc. announced robust full-year 2025 financial results, including 23% total revenue growth and a reduced net loss, alongside a strategic shift to hosted software and a path to positive adjusted EBITDA by 2028.

Summary

• Total revenue for full-year 2025 increased by 23.3% to $255.9 million, up from $207.5 million in 2024.
• Software revenue grew 10.6% to $199.5 million in 2025, while drug discovery revenue significantly increased to $56.4 million from $27.2 million in 2024.
• The net loss for 2025 substantially narrowed to $103.3 million, an improvement from a net loss of $187.1 million in 2024.
• Adjusted EBITDA for the full year 2025 improved to $(114.9) million, compared to $(152.5) million in 2024.
• Cash, cash equivalents, restricted cash, and marketable securities stood at $402.3 million as of December 31, 2025, an increase from $367.5 million at December 31, 2024.
• The company is accelerating its transition to a hosted software licensing model, which is expected to cause short-to-medium term declines in GAAP software revenue but will not impact ACV or cash flow.
• Schrdinger aims to achieve positive adjusted EBITDA by the end of 2028, supported by durable software ACV growth of 10-15% annually and disciplined operating expense management.
• The therapeutics portfolio is advancing, with 16 programs eligible for royalties and over $650 million in cash generated from drug discovery initiatives since 2020, with potential for nearly $5 billion in future milestones.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, reflecting significant financial improvements, robust underlying business growth (ACV), and strategic clarity towards future profitability, despite a temporary GAAP revenue dip due to a beneficial business model transition.

Positives

• Full-year 2025 total revenue increased by 23.3% to $255.9 million.
• Full-year 2025 software revenue grew by 10.6% to $199.5 million.
• Full-year 2025 drug discovery revenue more than doubled to $56.4 million from $27.2 million in 2024.
• Net loss significantly reduced to $103.3 million in 2025 from $187.1 million in 2024.
• Adjusted EBITDA improved to $(114.9) million in 2025 from $(152.5) million in 2024.
• Cash, cash equivalents, restricted cash, and marketable securities increased to $402.3 million by year-end 2025.
• Software Annual Contract Value (ACV) grew 4.0% to $198.5 million in 2025, with Top 20 Pharma ACV growing 15.3% to $80.8 million.
• Net Dollar Retention for Commercial Customers was 100% and Gross Dollar Retention was 96% in 2025.
• The company has 16 ongoing programs eligible for royalties and 20 collaborators since 2018.
• Positive topline Phase 2B data for aleniglipron (GLP-1 receptor agonist) from co-founded Structure Therapeutics, with Phase 3 expected mid-2026.
• AJ1-11095 (JAK2 inhibitor) from co-founded Ajax Therapeutics received orphan drug designation from the U.S. FDA for myelofibrosis.
• Positive topline Phase 3 results for zasocitinib (TYK2 inhibitor) from Takeda (acquired from co-founded Nimbus), with NDA filing intended for 2026, making Schrdinger eligible for future milestone payments.
• Introduced RetroSynth, an AI-driven solution for efficient molecule synthesis, and announced collaborations with Lilly TuneLab and Manas AI to enhance its platform's reach and capabilities.

Negatives

• Fourth quarter 2025 total revenue decreased by 1.2% to $87.2 million.
• Fourth quarter 2025 software revenue decreased by 13% to $69.3 million, primarily due to accelerated recognition of upfront revenue from multi-year agreements in 2024, partially offset by higher hosted revenue.
• Net Dollar Retention for Commercial Customers decreased to 100% in 2025 from 113% in 2024.
• The number of Commercial Customers (>$1M ACV) decreased from 29 in 2024 to 27 in 2025.
• The strategic transition to hosted software is expected to introduce short-to-medium term declines in GAAP software revenue, despite no impact on ACV or cash flow.

Risks

• Demand for the software platform may fluctuate.
• Ability to further develop the computational platform is crucial for continued growth.
• Reliance upon third-party providers of cloud-based infrastructure could pose operational risks.
• Successfully transitioning customers to hosted software deployments may face challenges.
• Factors adversely affecting the life sciences industry could impact business performance.
• Fluctuations in the value of the U.S. dollar and foreign currencies may affect financial results.
• Reliance upon third-party drug discovery collaborators introduces dependency risks.
• Uncertainties inherent in drug development and commercialization, including research activities, timing, and ability to complete preclinical studies and clinical trials.
• Whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials is uncertain.
• Uncertainties associated with the regulatory review of investigational new drug application submissions, clinical trials, and applications for marketing approvals.
• Ability to retain and hire key personnel is critical for operations and innovation.

Future Outlook

Schrdinger expects Software ACV for 2026 to range from $218 million to $228 million, representing 10-15% growth over 2025, and drug discovery revenue to be between $55 million and $65 million. Operating expenses are projected to be less than 2025. By the end of 2028, the company aims to achieve positive adjusted EBITDA, driven by durable annual software ACV growth of 10-15%, a substantially complete transition to hosted software, and a return of software gross margin percentage to the high 70s. Drug discovery revenue is targeted at $50 million annually, with potential variability.

Management Comments

• Ramy Farid, Ph.D., CEO: "Schrdingers performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide."
• Ramy Farid, Ph.D., CEO: "Looking ahead to 2026, we are poised to scale our impact through new platform enhancements and the commercial launch of our predictive toxicology solution."
• Richie Jain, CFO: "Our 2026 outlook and 2028 financial objectives reflect a strategic evolution in our business model... We are accelerating our transition to a hosted licensing model. This shift from upfront to ratable recognition is expected to establish a more predictable, higher-visibility revenue stream that better aligns with standard software business practices without impacting cash flow."
• Richie Jain, CFO: "During this transition, we believe ACV provides useful insight into the underlying trends and performance of our software business given the transitions impact on the timing of recognition of GAAP revenue, which we expect to decrease in the short-to-medium term."

Industry Context

StockSavvy.ai notes that Schrdinger's strong 2025 performance and strategic shift to a hosted software model align with broader trends in the software industry towards subscription-based, cloud-native solutions, which typically offer more predictable revenue streams. The continued growth in software ACV and significant advancements in its drug discovery pipeline, particularly with AI-driven solutions like RetroSynth and collaborations with major players like Lilly TuneLab, underscore the increasing importance of computational platforms in accelerating drug development. The company's focus on physics-based simulation combined with AI positions it uniquely in the rapidly expanding drug discovery AI landscape, differentiating it from competitors by emphasizing 'ground-truth' impact.

Comparison to Industry Standards

• Schrdinger's 10-15% annual software ACV growth target for 2026 and 2028 is competitive within the high-growth software-as-a-service (SaaS) sector, particularly for specialized enterprise software. Companies like Veeva Systems (VEEV) in life sciences cloud solutions often target similar or higher growth rates, though Schrdinger's unique blend of software and drug discovery makes direct comparisons complex.
• The transition to a hosted software model, with revenue converging with ACV, is an industry-standard move seen across many enterprise software providers (e.g., Adobe, Microsoft) to improve revenue predictability and customer experience, aligning Schrdinger with best practices in software delivery.
• The goal of achieving positive adjusted EBITDA by the end of 2028 demonstrates a commitment to profitability, a common objective for maturing SaaS companies, often following periods of significant investment in R&D and market expansion. This trajectory is comparable to other biotech software firms that have scaled their operations and moved towards sustainable profitability.
• The drug discovery pipeline's progress, including positive Phase 2B data for aleniglipron (GLP-1 receptor agonist) from Structure Therapeutics, positions Schrdinger's co-founded ventures favorably against other emerging biotech companies developing obesity treatments, a highly competitive and lucrative market. Success in these clinical stages is a critical benchmark for drug discovery firms.

Legal Proceedings

• Costs related to a derivative action and a settlement with a royalty partner were incurred in 2025, which management does not consider representative of ongoing operating performance.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through continued software ACV growth, drug discovery milestones, and a clear path to positive adjusted EBITDA, though short-term GAAP revenue may be impacted by the hosted transition.
• Customers: Expected benefits from the transition to hosted software, including faster onboarding, enhanced renewals, and improved support.
• Employees: No direct impact on employment or benefits mentioned, but continued investment in R&D and platform enhancements suggests ongoing innovation opportunities.
• Creditors: Improved cash position and a strategic focus on profitability by 2028 could enhance creditworthiness.

Next Steps

• Complete Phase 1 clinical packages for SGR-1505 and SGR-3515.
• Present initial SGR-3515 data in the second quarter of 2026.
• Explore strategic partnerships to advance the development of SGR-1505 and SGR-3515.
• Structure Therapeutics expects to initiate the aleniglipron Phase 3 program in mid-2026.
• Takeda intends to file a New Drug Application with the FDA for zasocitinib in 2026.
• Continue accelerating the transition to hosted software, with the majority of contracts expected to be hosted by 2028.
• Commercial launch of the predictive toxicology solution in 2026.
• Host a conference call on February 25, 2026, to discuss financial results and outlook.

Key Dates

Recommendation

The filing indicates a strong underlying business performance with significant improvements in net loss and adjusted EBITDA, robust software ACV growth, and a healthy cash position. The strategic shift to a hosted software model, while impacting short-term GAAP revenue, is a positive long-term move for predictability and customer experience. The therapeutics pipeline shows promising clinical advancements and substantial potential future milestones. These factors, combined with a clear objective to achieve positive adjusted EBITDA by 2028, suggest a strong growth trajectory and make the stock an attractive 'buy' for long-term investors, despite the temporary accounting-related revenue dip.

Keywords

Drug Discovery, AI, Machine Learning, Computational Platform, Software, Biotechnology, Pharmaceutical, Therapeutics, MALT-1 inhibitor, Wee1/Myt1 inhibitor, GLP-1 receptor agonist, JAK2 inhibitor, TYK2 inhibitor, Hosted Software, ACV, EBITDA, SEC Filing, Financial Results